A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

NCT06000891 · Terminated

Last updated 2026-05-28

This clinical trial is testing the safety and tolerability of the drug ZP7570 in human participants.

Status Terminated Stopped early and will not restart.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 84 people

Who can join Ages 18–64 · all sexes Healthy volunteers accepted.

Timeline Started 2023-09 · est. completion 2025-03

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT06000891 ↗

Description as written by the study sponsor.

The trial is a Phase 1, single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial including three cohorts in Part 1 in a semi-parallel design and one cohort in Part 2 in overweight and obese but otherwise healthy subjects, randomised to ZP7570 or placebo within each cohort where the observational period is 18 weeks for Part 1 and 28 weeks for Part 2. All subjects will be dosed for 13 weeks in Part 1 and for 28 weeks in Part 2 with ascending weekly doses of ZP7570 at dose levels with corresponding volume of placebo.

Treatments tested

ZP7570 also known as GLP-1/GLP-2 agonist Drug

13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
Placebo Drug

13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.

Main thing measured	Incidence of treatment emergent adverse events (TEAEs)
Sponsor	Zealand Pharma
Conditions studied	Safety and Tolerability
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06000891 ↗